Skip to main content
Erschienen in: Cancer Causes & Control 10/2012

01.10.2012 | Original paper

Estimating prevalence of distant metastatic breast cancer: a means of filling a data gap

verfasst von: Mark S. Clements, David M. Roder, Xue Qin Yu, Sam Egger, Dianne L. O’Connell

Erschienen in: Cancer Causes & Control | Ausgabe 10/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To develop and validate a method for estimating numbers of people with distant cancer metastases, for evidence-based service planning.

Methods

Estimates were made employing an illness-death model with distant metastatic cancer as the illness state- and site-specific mortality as an outcome, using MIAMOD software. To demonstrate the method, we estimated numbers of females alive in Australia following detection of distant metastatic breast cancer during 1980–2004, using data on patient survival from an Australian population-based cancer registry. We validated these estimates by comparing them with direct prevalence counts.

Results

Relative survival at 10 years following detection of distant metastases was low (5–20 %), with better survival experienced by: (1) females where distant metastatic disease was detected at initial diagnosis rather than subsequently (e.g., at recurrence); (2) those diagnosed in more recent calendar years; and (3) younger age groups. For Australian females aged less than 85 years, the modeled cumulative risk of detection of distant metastatic breast cancer (either at initial diagnosis or subsequently) declined over time, but numbers of cases with this history rose from 71 per 100,000 in 1980 to 84 per 100,000 in 2004. The model indicated that there were approximately 3–4 prevalent distant metastatic breast cancer cases for every breast cancer death. Comparison of estimates with direct prevalence counts showed a reasonable level of agreement.

Conclusions

The method is straightforward to apply and we recommend its use for breast and other cancers when registry data are insufficient for direct prevalence counts. This will provide estimates of numbers of people who would need ongoing medical surveillance and care following detection of distant metastases.
Literatur
1.
Zurück zum Zitat Ries LAG (2007) Cancer survival among adults: US SEER program, 1988–2001, patient and tumor characteristics. Bethesda, MD: U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute Ries LAG (2007) Cancer survival among adults: US SEER program, 1988–2001, patient and tumor characteristics. Bethesda, MD: U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute
2.
Zurück zum Zitat Capocaccia R, Colonna M, Corazziari I et al (2002) Measuring cancer prevalence in Europe: the EUROPREVAL project. Ann Oncol 13:831–839PubMedCrossRef Capocaccia R, Colonna M, Corazziari I et al (2002) Measuring cancer prevalence in Europe: the EUROPREVAL project. Ann Oncol 13:831–839PubMedCrossRef
3.
Zurück zum Zitat Barendregt JJ, Van Oortmarssen GJ, Vos T, Murray CJ (2003) A generic model for the assessment of disease epidemiology: the computational basis of DisMod II. Popul Health Metr 1:4PubMedCrossRef Barendregt JJ, Van Oortmarssen GJ, Vos T, Murray CJ (2003) A generic model for the assessment of disease epidemiology: the computational basis of DisMod II. Popul Health Metr 1:4PubMedCrossRef
4.
Zurück zum Zitat Yabroff KR, Lamont EB, Mariotto A et al (2008) Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst 100:630–641PubMedCrossRef Yabroff KR, Lamont EB, Mariotto A et al (2008) Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst 100:630–641PubMedCrossRef
5.
Zurück zum Zitat Verdecchia A, Capocaccia R, Egidi V, Golini A (1989) A method for the estimation of chronic disease morbidity and trends from mortality data. Stat Med 8:201–216PubMedCrossRef Verdecchia A, Capocaccia R, Egidi V, Golini A (1989) A method for the estimation of chronic disease morbidity and trends from mortality data. Stat Med 8:201–216PubMedCrossRef
6.
Zurück zum Zitat Keiding N (1991) Age-specific incidence and prevalence: a statistical perspective (with discussion). J R Statist Soc A 154:371–412CrossRef Keiding N (1991) Age-specific incidence and prevalence: a statistical perspective (with discussion). J R Statist Soc A 154:371–412CrossRef
7.
Zurück zum Zitat Gail MH, Kessler L, Midthune D, Scoppa S (1999) Two approaches for estimating disease prevalence from population-based registries of incidence and total mortality. Biometrics 55:1137–1144PubMedCrossRef Gail MH, Kessler L, Midthune D, Scoppa S (1999) Two approaches for estimating disease prevalence from population-based registries of incidence and total mortality. Biometrics 55:1137–1144PubMedCrossRef
8.
Zurück zum Zitat Tracey E, Alam N, Chen W, Bishop J (2008) Cancer in New South Wales: incidence and mortality 2006. Cancer Institute NSW, Sydney Tracey E, Alam N, Chen W, Bishop J (2008) Cancer in New South Wales: incidence and mortality 2006. Cancer Institute NSW, Sydney
9.
Zurück zum Zitat Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277–300PubMedCrossRef Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277–300PubMedCrossRef
10.
Zurück zum Zitat De Angelis G, De Angelis R, Frova L, Verdecchia A (1994) MIAMOD: a computer package to estimate chronic disease morbidity using mortality and survival data. Comput Methods Programs Biomed 44:99–107PubMedCrossRef De Angelis G, De Angelis R, Frova L, Verdecchia A (1994) MIAMOD: a computer package to estimate chronic disease morbidity using mortality and survival data. Comput Methods Programs Biomed 44:99–107PubMedCrossRef
11.
Zurück zum Zitat Grande E, Inghelmann R, Francisci S et al (2006) Estimating regional cancer burden in countries with partial registration coverage: an application to all malignant neoplasms in Italy over the period 1970–2010. Eur J Cancer 42:3236–3245PubMedCrossRef Grande E, Inghelmann R, Francisci S et al (2006) Estimating regional cancer burden in countries with partial registration coverage: an application to all malignant neoplasms in Italy over the period 1970–2010. Eur J Cancer 42:3236–3245PubMedCrossRef
12.
Zurück zum Zitat De Angelis R, Grande E, Inghelmann R et al (2007) Cancer prevalence estimates in Italy from 1970 to 2010. Tumori 93:392–397PubMed De Angelis R, Grande E, Inghelmann R et al (2007) Cancer prevalence estimates in Italy from 1970 to 2010. Tumori 93:392–397PubMed
13.
Zurück zum Zitat Australian Institute of Health and Welfare, Cancer Australia, Australasian Association of Cancer Registries (2008) Cancer Survival and Prevalence in Australia: Cancers diagnosed from 1982 to 2004. Canberra: AIHW Australian Institute of Health and Welfare, Cancer Australia, Australasian Association of Cancer Registries (2008) Cancer Survival and Prevalence in Australia: Cancers diagnosed from 1982 to 2004. Canberra: AIHW
14.
Zurück zum Zitat Perme MP, Stare J, Esteve J (2012) On estimation in relative survival. Biometrics 68:113–120PubMedCrossRef Perme MP, Stare J, Esteve J (2012) On estimation in relative survival. Biometrics 68:113–120PubMedCrossRef
15.
Zurück zum Zitat Brenner H, Gefeller O, Hakulinen T (2004) Period analysis for ‘up-to-date’ cancer survival data: theory, empirical evaluation, computational realisation and applications. Eur J Cancer 40:326–335PubMedCrossRef Brenner H, Gefeller O, Hakulinen T (2004) Period analysis for ‘up-to-date’ cancer survival data: theory, empirical evaluation, computational realisation and applications. Eur J Cancer 40:326–335PubMedCrossRef
16.
Zurück zum Zitat De Angelis R, Capocaccia R, Hakulinen T, Soderman B, Verdecchia A (1999) Mixture models for cancer survival analysis: application to population- based data with covariates. Stat Med 18:441–454PubMedCrossRef De Angelis R, Capocaccia R, Hakulinen T, Soderman B, Verdecchia A (1999) Mixture models for cancer survival analysis: application to population- based data with covariates. Stat Med 18:441–454PubMedCrossRef
17.
Zurück zum Zitat Yu B, Tiwari RC, Cronin KA, McDonald C, Feuer EJ (2005) CANSURV: A Windows program for population-based cancer survival analysis. Comput Methods Programs Biomed 80:195–203PubMedCrossRef Yu B, Tiwari RC, Cronin KA, McDonald C, Feuer EJ (2005) CANSURV: A Windows program for population-based cancer survival analysis. Comput Methods Programs Biomed 80:195–203PubMedCrossRef
18.
Zurück zum Zitat Lambert PC, Thompson JR, Weston CL, Dickman PW (2007) Estimating and modeling the cure fraction in population-based cancer survival analysis. Biostatistics 8:576–594PubMedCrossRef Lambert PC, Thompson JR, Weston CL, Dickman PW (2007) Estimating and modeling the cure fraction in population-based cancer survival analysis. Biostatistics 8:576–594PubMedCrossRef
19.
Zurück zum Zitat Brenner H, Hakulinen T (2004) Are patients diagnosed with breast cancer before age 50 years ever cured? J Clin Oncol 22:432–438PubMedCrossRef Brenner H, Hakulinen T (2004) Are patients diagnosed with breast cancer before age 50 years ever cured? J Clin Oncol 22:432–438PubMedCrossRef
Metadaten
Titel
Estimating prevalence of distant metastatic breast cancer: a means of filling a data gap
verfasst von
Mark S. Clements
David M. Roder
Xue Qin Yu
Sam Egger
Dianne L. O’Connell
Publikationsdatum
01.10.2012
Verlag
Springer Netherlands
Erschienen in
Cancer Causes & Control / Ausgabe 10/2012
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-012-0040-9

Weitere Artikel der Ausgabe 10/2012

Cancer Causes & Control 10/2012 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.